Lord, Abbett & Co
NXTM

Lord, Abbett & Co’s NxStage Medical Inc. NXTM Stock Holding History

Lord, Abbett & Co’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-117,890
Closed -$3.16M – 961
2017
Q1 		$3.16M Sell
117,890
-1,326
-1% -$36.6K 0.01% 804
2016
Q4 		$3.13M Buy
119,216
+1,392
+1% +$34.4K 0.01% 807
2016
Q3 		$2.94M Sell
117,824
-141,643
-55% -$3.3M 0.01% 806
2016
Q2 		$5.63M Buy
259,467
+100,250
+63% +$1.79M 0.02% 681
2016
Q1 		$2.39M Sell
159,217
-305,886
-66% -$5.13M 0.01% 818
2015
Q4 		$10.2M Buy
465,103
+52,437
+13% +$977K 0.03% 593
2015
Q3 		$6.51M Sell
412,666
-1,000,007
-71% -$16M 0.02% 676
2015
Q2 		$20.2M Sell
1,412,673
-1,237,078
-47% -$21M 0.05% 481
2015
Q1 		$45.8M Sell
2,649,751
-320,895
-11% -$5.67M 0.12% 269
2014
Q4 		$53.3M Buy
2,970,646
+2,522,509
+563% +$40.6M 0.14% 206
2014
Q3 		$5.88M Buy
448,137
+187,429
+72% +$2.52M 0.01% 713
2014
Q2 		$3.75M Buy
+260,708
New +$3.4M 0.01% 851

Other funds holding NXTM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

Lord, Abbett & Co's NXTM Position: Q2 2017 in Review

Lord, Abbett & Co sold out of NxStage Medical Inc. (NXTM) in Q2 2017, closing a stake of 117,890 shares — an estimated $3.16M sold.

Lord, Abbett & Co first reported a position in NXTM in Q2 2014 and held it in 12 quarters. The position peaked at $53.3M in Q4 2014. 163 funds tracked by Wall St. Rank hold NXTM as of Q2 2017.

  • Lord, Abbett & Co reported no remaining NxStage Medical Inc. position as of Q2 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 117,890 NxStage Medical Inc. shares in Q2 2017, an estimated $3.16M.
  • Lord, Abbett & Co first reported a position in NxStage Medical Inc. in Q2 2014 and held it in 12 quarters.
  • Lord, Abbett & Co's NxStage Medical Inc. position peaked at $53.3M in Q4 2014.
  • 163 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q2 2017.

Based on Lord, Abbett & Co's 13F filing for Q2 2017, filed 14 Aug 2017.